Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

| 控股股东姓名 | 国籍 | 是否取得其他国家或地区居留权 | | --- | --- | --- | | 帅放文 | 中国 | 合 | | 主要职业及职务 | 帅放文先生于2003年创办本公司,为公司创始人,现任公司董事长。 | | | 报告期内控股和参股的其他境内外上 | 不适用 | | | 市公司的股权情况 | | | 中国经济网北京9月30日讯 尔康制药(300267.SZ)昨晚披露了关于控股股东减持公司股份的预披露公告。 公司控股股东帅放文持有公司股份853,574,906股，占公司总股本的41.38%，计划在公告发布之日起15个交易 日后的3个月内（即2025年10月29日至2026年1月28日）以集中竞价或大宗交易方式合计减持公司股份不超过 42,000,000股，即不超过公司总股本的2.04%。以上股东在任意连续九十个自然日内通过证券交易所集中竞价交易 减持股份的总数，不超过公司股份总数的1%；在任意连续九十个自然日内，通过大宗交易方式减持股份的总数， 不超过公司股份总数的2%。 按尔康制药9月29日的收盘价3.49元计算，帅放文本次拟套现1.47亿元。 据尔康制药2024年年报，公司控股股 ...

Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]

来源：格隆汇 温馨提示：财经最新动态随时看，请关注金投网APP。 | | | 9月30日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 | 主要内容 | | | 森廟传感 | 实际控制人之一致行动人拟减持不超过1.09%股份 | | | 尔康制药 | 控股股东拟减持不超过2.04%股份 | | | 安德利 | BVI东华拟减持不超1.00%股份 | | | 智洋创新 | 控股股东及其一致行动人拟减持合计不超过422.5万股 | | | 振江股份 | 胡震拟减持不超3%股份 | | | 四川黄金 | 北京金阳拟减持不超过1.8%股份 | | 股东减持 | 燕麦科技 | 实际控制人、控股股东刘燕合计减持1. 2897%公司股份 | | | 国机重装 | 中行德阳分行、中行镇江润州支行拟减持合计不超1%股份 | | | 经纬恒海 | 监事崔文革拟减持不超60万股 | | | 新相微 | 科宏芯拟减持不超1%股份 | | | 武进不锈 | 3名高管拟合计减持不超62.34万股公司股份 | | | 美心晟 | 股东WI Harper Fund VII拟减持不超1%股份 | | | 中润光 ...

Mergers and Acquisitions - DiAo Micro plans to acquire equity in Rongpai Semiconductor through a combination of issuing shares and cash payment, with the stock suspended for up to 10 trading days [1] - Jingye Intelligent intends to purchase 51% of Hefei Shengwen for 108 million yuan, aiming to enhance its strategic presence in the military sector [2] - Guolin Technology is planning a cash acquisition of 91.07% of Xinjiang Kailianjie, which specializes in the production of maleic anhydride, potentially creating a synergistic relationship with its existing business [3] Shareholding Changes - Erkang Pharmaceutical's controlling shareholder plans to reduce holdings by up to 42 million shares, representing 2.04% of the total share capital [4] - Senba Sensor's actual controller's associated party intends to reduce holdings by no more than 308.69 thousand shares, accounting for 1.09% of the total share capital [5] - Zhiyang Innovation's controlling shareholder and associated parties plan to reduce holdings by up to 422.5 thousand shares, which is 1.82% of the total share capital, during a specified period [6] Regulatory Issues - Youkeshu announced that three shareholders are under investigation by the China Securities Regulatory Commission for failing to disclose significant information [7] - *ST Xingnong received a notice from the China Securities Regulatory Commission regarding an investigation for suspected information disclosure violations, while its operations remain normal [8] - *ST Mubang's actual controller is also under investigation by the China Securities Regulatory Commission for failing to disclose non-operational fund transactions [10]

智通财经APP讯，尔康制药(300267.SZ)公告，公司控股股东帅放文计划在公告发布之日起15个交易日后 的3个月内(即2025年10月29日至2026年1月28日)以集中竞价或大宗交易方式合计减持公司股份不超过 4200万股，即不超过公司总股本的2.04%。 ...

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, within a three-month period starting from October 29, 2025, to January 28, 2026 [1] Summary by Relevant Categories Shareholder Actions - Shuai Fangwen intends to reduce his holdings through centralized bidding or block trading methods [1] Share Capital Impact - The planned reduction amounts to a maximum of 42 million shares, which is equivalent to 2.04% of the company's total share capital [1]

格隆汇9月29日丨尔康制药(300267.SZ)公布，公司控股股东帅放文先生持有公司股份853,574,906股，占 本公司总股本的41.38%，计划在本公告发布之日起15个交易日后的3个月内（即2025年10月29日至2026 年1月28日）以集中竞价或大宗交易方式合计减持公司股份不超过42,000,000股，即不超过本公司总股本 的2.04%。 ...

Group 1 - The core point of the news is that Hunan Erkang Pharmaceutical Co., Ltd. announced a pre-disclosure regarding the reduction of shares by its controlling shareholder, Shuai Fangwen, due to personal funding needs [1][2]. Group 2 - Shuai Fangwen holds 853,574,906 shares, accounting for 41.38% of the company's total share capital [2]. - The reduction plan details include a maximum reduction of 42,000,000 shares, which represents 2.04% of the total share capital, within a specified period from October 29, 2025, to January 28, 2026 [2]. - The reduction will be executed through centralized bidding and block trading, with limits on the total number of shares that can be sold in a 90-day period [2].

人民财讯9月29日电，尔康制药（300267）9月29日公告，持股41.38%的公司控股股东帅放文，计划在 15个交易日后的3个月内，以集中竞价或大宗交易方式合计减持公司股份不超过4200万股，即不超过公 司总股本的2.04%。 ...